Yuxiang Ma

6.0k total citations · 1 hit paper
166 papers, 3.8k citations indexed

About

Yuxiang Ma is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Yuxiang Ma has authored 166 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 110 papers in Oncology, 85 papers in Pulmonary and Respiratory Medicine and 25 papers in Molecular Biology. Recurrent topics in Yuxiang Ma's work include Lung Cancer Treatments and Mutations (70 papers), Lung Cancer Research Studies (35 papers) and Cancer Immunotherapy and Biomarkers (33 papers). Yuxiang Ma is often cited by papers focused on Lung Cancer Treatments and Mutations (70 papers), Lung Cancer Research Studies (35 papers) and Cancer Immunotherapy and Biomarkers (33 papers). Yuxiang Ma collaborates with scholars based in China, United States and Japan. Yuxiang Ma's co-authors include Hongyun Zhao, Yunpeng Yang, Yan Huang, Wenfeng Fang, Shaodong Hong, Yuanyuan Zhao, Li Zhang, Ting Zhou, Xue Hou and Jianhua Zhan and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Yuxiang Ma

158 papers receiving 3.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials

2018 326 citations Wenfeng Fang, Yunpeng Yang et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yuxiang Ma China	32	2.2k	1.2k	804	592	504	166	3.8k
Brett Hughes Australia	31	2.3k 1.1×	2.1k 1.7×	820 1.0×	349 0.6×	696 1.4×	179	4.4k
Alessandro Ottaiano Italy	33	1.7k 0.8×	569 0.5×	831 1.0×	838 1.4×	468 0.9×	194	3.5k
Kostas Syrigos Greece	30	1.6k 0.8×	1.1k 0.9×	1.0k 1.3×	211 0.4×	428 0.8×	114	3.3k
Young‐Chul Kim South Korea	33	2.2k 1.0×	1.9k 1.5×	878 1.1×	373 0.6×	474 0.9×	241	4.1k
Su‐Mei Cao China	18	1.1k 0.5×	605 0.5×	907 1.1×	234 0.4×	642 1.3×	47	2.6k
Alexander Barsouk United States	15	1.0k 0.5×	1.1k 0.9×	1.1k 1.4×	209 0.4×	446 0.9×	23	3.2k
Seung Tae Kim South Korea	35	2.4k 1.1×	1.9k 1.5×	1.2k 1.5×	367 0.6×	1.0k 2.1×	286	4.9k
Tadashi Mio Japan	33	1.7k 0.8×	1.9k 1.6×	653 0.8×	423 0.7×	364 0.7×	156	3.8k
Kalyan Saginala United States	12	880 0.4×	1.0k 0.8×	1.0k 1.3×	190 0.3×	424 0.8×	13	2.9k
Teresa A. Goldin United States	4	1.9k 0.8×	1.2k 1.0×	2.1k 2.6×	338 0.6×	1.3k 2.5×	5	4.7k

Countries citing papers authored by Yuxiang Ma

Since Specialization

Citations

This map shows the geographic impact of Yuxiang Ma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuxiang Ma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuxiang Ma more than expected).

Fields of papers citing papers by Yuxiang Ma

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yuxiang Ma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuxiang Ma. The network helps show where Yuxiang Ma may publish in the future.

Co-authorship network of co-authors of Yuxiang Ma

This figure shows the co-authorship network connecting the top 25 collaborators of Yuxiang Ma. A scholar is included among the top collaborators of Yuxiang Ma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yuxiang Ma. Yuxiang Ma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wei, Xiaoli, Dan‐Yun Ruan, Feng Wang, et al.. (2025). First-in-human phase 1 study of an orally bioavailable vascular-disrupting agent DX1002 in patients with advanced solid tumors. Cell Reports Medicine. 6(2). 101969–101969. 1 indexed citations

Ma, Yuxiang, et al.. (2025). Modeling of the multi-period two-stage green hydrogen supply chain with consideration of supply and demand uncertainties. International Journal of Hydrogen Energy. 129. 297–314. 3 indexed citations

Ma, Yuxiang, Huaqiang Zhou, Fan Luo, et al.. (2024). Remodeling the tumor-immune microenvironment by anti-CTLA4 blockade enhanced subsequent anti-PD-1 efficacy in advanced nasopharyngeal carcinoma. npj Precision Oncology. 8(1). 65–65. 6 indexed citations

Zhao, Haobin, Yuxiang Ma, Xiao‐Ming Meng, et al.. (2024). 605O YL201, a novel B7H3-targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors: Results from a first-in-human phase I study. Annals of Oncology. 35. S485–S485. 4 indexed citations

Gao, Yan, et al.. (2024). Efficacy and safety of intrathecal dexamethasone combined with isoniazid in the treatment of tuberculous meningitis: a meta-analysis. BMC Neurology. 24(1). 194–194.

Fang, Wenfeng, Yunpeng Yang, Yan Huang, et al.. (2023). 74P A single-center, phase II study of surufatinib combined with toripalimab, pemetrexed(A), and platinum (P) in patients with advanced non-squamous non-small cell lung cancer (nsq-NSCLC). Immuno-Oncology Technology. 20. 100546–100546. 1 indexed citations

Ma, Yuxiang, Qun Chen, Yang Zhang, et al.. (2023). Pharmacokinetics, safety, tolerability, and feasibility of apatinib in combination with gefitinib in stage IIIB-IV EGFR-mutated non-squamous NSCLC: a drug-drug interaction study. Cancer Chemotherapy and Pharmacology. 92(5). 411–418. 1 indexed citations

Zhao, Yuanyuan, Yuxiang Ma, Yun Fan, et al.. (2023). A multicenter, open-label phase Ib/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non–small-cell lung cancer (AK104-202 study). Lung Cancer. 184. 107355–107355. 37 indexed citations

Ma, Yuxiang, Yuanyuan Zhao, Yang Zhang, et al.. (2023). Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer. 11(6). e006654–e006654. 34 indexed citations

10.

Zhang, Li, Yuxiang Ma, Yuanyuan Zhao, et al.. (2023). 1316MO BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate, in patients with non-small cell lung cancer: Updated results from first-in-human phase I study. Annals of Oncology. 34. S758–S758. 9 indexed citations

11.

Liu, Jiali, Yuxiang Ma, Xia Liu, et al.. (2022). Prognostic effects of health-related quality of life at baseline and early change in health-related quality of life on response to treatment and survival in patients with advanced lung cancer: a prospective observational study in China. BMJ Open. 12(2). e047611–e047611. 4 indexed citations

12.

Xu, Fang, Yuxiang Ma, Jian Gao, et al.. (2020). Typically inhibiting USP14 promotes autophagy in M1-like macrophages and alleviates CLP-induced sepsis. Cell Death and Disease. 11(8). 666–666. 30 indexed citations

13.

Zhang, Zhonghan, Yang Zhang, Fan Luo, et al.. (2020). Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a first‐line treatment for advanced EGFR‐mutant non‐small cell lung cancer. SHILAP Revista de lepidopterología. 10(2). e33–e33. 15 indexed citations

14.

Fang, Wenfeng, Yuxiang Ma, Jiani C. Yin, et al.. (2019). Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti–PD-(L)1 Therapies in Non–Small Cell Lung Cancer. Clinical Cancer Research. 25(16). 5015–5026. 139 indexed citations

15.

Zhang, Zhonghan, Fan Luo, Yang Zhang, et al.. (2019). The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706). Cancer Communications. 39(1). 69–69. 18 indexed citations

16.

Zhao, Jing, Yuxiang Ma, Yingjie Zhang, et al.. (2019). Low-dose 2-deoxyglucose and metformin synergically inhibit proliferation of human polycystic kidney cells by modulating glucose metabolism. Cell Death Discovery. 5(1). 76–76. 40 indexed citations

17.

Hu, Zhihuang, Wenhua Liang, Yunpeng Yang, et al.. (2016). Personalized Estimate of Chemotherapy-Induced Nausea and Vomiting. Medicine. 95(2). e2476–e2476. 18 indexed citations

18.

Ma, Yuxiang, Yunpeng Yang, Yan Huang, et al.. (2014). An investigation of symptom burden and quality of life in Chinese chemo-naïve advanced lung cancer patients by using the Instrument-Cloud QOL System. Lung Cancer. 84(3). 301–306. 10 indexed citations

19.

Ma, Liang‐Xiao, Yuxiang Ma, Yuxia Ma, et al.. (2010). Immediate Effect of Acupuncture at Sanyinjiao (SP6) and Xuanzhong (GB39) on Uterine Arterial Blood Flow in Primary Dysmenorrhea. The Journal of Alternative and Complementary Medicine. 16(10). 1073–1078. 31 indexed citations

20.

Li, Lou, et al.. (2006). US findings of bilateral primary breast cancer: Retrospective study. European Journal of Radiology. 61(1). 154–157. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact